We‘re more than a manufacturer.
When you partner with Ipsen, you get the support and rescoureces of an entire team dedicated to your success.
From sales and service, to project management, engineering, production and quality control, we are committed to delivering an exceptional customer experience.

Advanced Engineering Solutions
Ipsen‘s Engineering Team has the experience and resources to design and manufacture innovative, highly technical atmosphere and vacuum.

About us
Backed by more than 70 years of experience, our mission is to strengthen heat treatment through expert-driven solutions.
Much like our founder, Harold Ipsen, we believe that innovation drives excellence. We are committed to delivering proven technology for a range of applications that enable you to transform space exploration, improve titanium medical implants and develop more efficient cars and jet engines.
Through our global partnerships, we provide unmatched service and support for all your needs.

Find our imprint on http://www.ipsenglobal.com/en/imprint/

Ipsen International GmbH

𝟳𝟱𝘁𝗵 𝗮𝗻𝗻𝗶𝘃𝗲𝗿𝘀𝗮𝗿𝘆 𝗼𝗳 𝗜𝗽𝘀𝗲𝗻 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗚𝗺𝗯𝗛 - 𝗮 𝗱𝗮𝘆 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗲𝗺𝗽𝗹𝗼𝘆𝗲𝗲𝘀
 
Video: https://lnkd.in/e5rpJN5c
The 75th anniversary of Ipsen International GmbH was an unforgettable day for all employees. 
We started with a common breakfast and got interesting insights into heat technology and latest software developments by our colleagues 
𝗛𝗲𝗿𝗯𝗲𝗿𝘁 𝗛𝗮𝗻𝘀 𝗮𝗻𝗱 𝗔𝗿𝗻𝗱𝘁 𝗪𝗲𝘁𝘇𝗲𝗹. Then we opened together with the minister Mona Neubaur the new technical center "Future Lab" and we  received exclusive explanations about our innovations. 
 
To round off the day in a informal atmosphere, we formed groups and took part in an exciting iPad rally. Within a radius of 2 km, our teams answered questions and solved tasks. There was a lot of fun and laughter before we returned to Ipsen after 1.5 hours. The winning team was rewarded with a check worth 800€ for another team event. 
In bright sunshine, we ended the day together and all agreed: This day was a complete success and has welded us even closer together as a team.

𝗜𝗺𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻𝘀 "𝗧𝗵𝗲 𝗘𝘃𝗲𝗻𝘁 𝗢𝗳 𝗧𝗵𝗲 𝗬𝗲𝗮𝗿 𝗶𝗻 𝗛𝗲𝗮𝘁 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁: 𝗜𝗽𝘀𝗲𝗻 -𝗠𝗲𝗲𝘁 𝘁𝗵𝗲 𝗛𝗲𝗮𝘁 𝟮𝟬𝟮𝟯”
What an incredible event! Thank you to everyone who made our Meet the Heat 2023 event such a success. We were so happy to see so many familiar faces and meet new ones too! From our amazing speakers to our dedicated attendees, we couldn't have done it without you all.

#ipsenglobal #ics #mth2023

Ipsen Meet the Heat - Podiumsdiskussion mit Prof. Dr. Dudenhöffer / Prof. Dr. Pfeifer / Paul van Doesburg und Dr Bora Özkan.

𝗙𝗶𝗿𝘀𝘁 𝗶𝗺𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻𝘀 𝗼𝗳 𝗜𝗽𝘀𝗲𝗻 - 𝗠𝗲𝗲𝘁 𝘁𝗵𝗲 𝗛𝗲𝗮𝘁! From insightful presentations to engaging discussions, our first day at Ipsen-Event Meet the Heat 2023 left us feeling inspired and motivated!  Looking forward to seeing where this journey takes us next! 

#ipsenglobal #ics #mth2023

𝗡𝗥𝗪-𝗠𝗶𝗻𝗶𝘀𝘁𝗲𝗿𝗶𝗻 𝗠𝗼𝗻𝗮 𝗡𝗲𝘂𝗯𝗮𝘂𝗿 𝘄𝗲𝗶𝗵𝘁 𝗱𝗮𝘀 𝗙𝘂𝘁𝘂𝗿𝗲 𝗟𝗮𝗯 𝗱𝗲𝗿 𝗙𝗶𝗿𝗺𝗮 𝗜𝗽𝘀𝗲𝗻 𝗚𝗺𝗯𝗛 𝘄ä𝗵𝗿𝗲𝗻𝗱 𝗱𝗲𝗿 𝟳𝟱- 𝗷ä𝗵𝗿𝗶𝗴𝗲𝗻 𝗝𝘂𝗯𝗶𝗹ä𝘂𝗺𝘀𝗳𝗲𝗶𝗲𝗿 𝗲𝗶𝗻

Kleve: 18.09.2023 - Feierstimmung bei Ipsen International: Das Traditionsunternehmen aus Kleve lud am Montag seine Mitarbeiter und Mitarbeiterinnen zum 75-jährigen Bestehen der Firma ein. Am Mittag traf noch ein weiterer prominenter Gast ein: NRW-Wirtschaftsministerin Mona Neubaur tauschte sich mit Unternehmensvertretern über Chancen des Maschinenbaus als Enabler für den Klimaschutz aus.
Das Maschinen- und Anlagenbauunternehmen Ipsen besteht seit 1948 und ist heute eine international agierende Unternehmensgruppe, die zu den Marktführern in der Wärmebehandlungstechnik zählt. Das Unternehmen baut Industrieöfen und Anlagen zur Wärmebehandlung von Bauteilen und Komponenten und feierte sein 75-jähriges Bestehen. 
„Mit dem Ipsen Future Lab haben wir ein weltweit erstes Technikum entwickelt, in dem Hybrid-Industrieöfen präsentieren werden, die neben Propan, LPG, LNG auch zu 100 % mit Wassersoff betrieben werden können. Mit dieser neuen Generation von Wärmebehandlungsanlagen wird ein wichtiger Beitrag für den Klimaschutz und zur Verbesserung der Luftqualität geleistet. Neben der Energieeinsparung werden klima- und gesundheitsschädliche Abgase wie Kohlendioxide und Stickoxide deutlich reduziert“ so der Geschäftsführer Paul van Doesburg. 
Die Veranstaltung bot eine gute Gelegenheit für Mitarbeiterinnen und Mitarbeiter das neue Future Lab kennenzulernen. Untermauert wurde die Einweihung mit verschieden Vorträgen zur Wärmetechnik und zu den Besonderheiten des Ipsen Future Labs. 
Für das Unternehmen gehörte der Besuch von Wirtschafts- und Klimaschutzministerin Mona Neubaur zu den Höhepunkten des Tages. Die Ministerin weihte das Ipsen Future Lab ein: „Wasserstoff ist ein entscheidender Baustein für die klimaneutrale Transformation unserer Wirtschaft und ein riesiger Wachstumsmarkt und eröffnen dem Maschinen- und Anlagenbau enorme Chancen. Innovative Verfahren leisten einen entscheidenden Beitrag für klimafreundliche Industrieprozesse und stärken die Wettbewerbsfähigkeit unserer starken Maschinenbauunternehmen in Nordrhein-Westfalen. Das ist ein wichtiger Schritt auf dem Weg Nordrhein-Westfalens zum ersten klimaneutralen Industriestandort Europas.“

#IpsenGlobal #Neubaur #NRW-Ministerium #Neubaur

Technology. Innovation. Service
Werden Sie Teil unseres erfolgreichen Teams: Ihre Karriere bei Ipsen.
https://lnkd.in/essYk6z8

Ipsen - Meet the Heat 20. & 21. Sept. 2023

Registration: www.ipsen-mth2023.de/en

#ipsenglobal #mth2023 #energyefficiency #ics

𝗜𝗽𝘀𝗲𝗻 - 𝗠𝗲𝗲𝘁 𝘁𝗵𝗲 𝗛𝗲𝗮𝘁 - 𝟮𝟬. & 𝟮𝟭. 𝗦𝗲𝗽𝘁. 𝟮𝟬𝟮𝟯 the event of the year in heat treatment is reaching its full capacity of 𝟯𝟬𝟬 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁𝘀. All interested attendees from the heat treatment industry who will have the privilege to see the first furnace with CO2 neutral heating system.
www.ipsen-mth2023.de\en

#ipsenglobal #ipsengermany #ics #mth2023 #energyefficiency

𝗜𝗽𝘀𝗲𝗻 - 𝗠𝗲𝗲𝘁 𝘁𝗵𝗲 𝗛𝗲𝗮𝘁 𝟮𝟬. & 𝟮𝟭. 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟮𝟬𝟮𝟯

The hottest answer to CO2-optimized heat treatment: 
Ipsen-ATLAS Green (Hybrid furnace)

Come and see: www.ipsen-mth2023.de/en

#ipsenGlobal #ics #hydrogen #heattreatment

Symtomkollen

Ipsen

NutropinAq

IPhone / Mobile Compatible

Viewport Meta

Domain Not Resolving

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

Euro

HSTS

Google Maps

Content Delivery Network

Chief Executive Officer

David Loew

Legal

Francois Garnier

Guesthouse Owner

Frédéric Lebigre

Acting Chief of Staff and Head of Operations, US Neuroscience Franchise

Jace HUANG

Business Management

Jennifer Benenson

Jennifer Pantina

Associate General Counsel

Jesse Siegel

Senior Director, Global Partnering

Jordan Gass

Quality

Karine Roth

Founder

Lucky Young

Saran Muthiah

Paul Sekhri

Marc de Garidel

JoëL Richard

Michele Ollier

Eric Ducamp

Elisabeth Vey

Analytical Development Leader

Sandra Silvestri

EVP, Chief Medical Officer, Head of Global Medical Affairs, Patient Safety & Patient Affairs

Philippe Lopes-Fernandes

Executive Vice President, Chief Business Officer, Member of the Executive Committee

Paul Murasko

Head of Digital Customer Interaction for North America

Aurélie Martin

Bioinformatics Engineer

Dominique Brard

Executive Vice President, Human Resources

Tim Bourque

Associate Director of Warehousing & Logistics

Christophe Jean

Executive Vice President, Strategy and Business Development

Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.

Pyxis Oncology is  a developer of antibody therapeutics intended to promote the body's immune response to cancer.

Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics

Motus Therapeutics is a biotechnology company developing peptide therapeutics for the treatment of metabolic diseases.

Syntaxin engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases.

Biotechnology Companies With More Than $1B in Revenue

France Public Companies With More Than $500 in Revenue

France Public Companies With More Than $50M in Revenue

Biotechnology Public Companies With More Than $1M in Revenue

Ipsen is a global specialty-driven biopharmaceutical company focused on innovation and specialty care. Ipsen develops and commercializes innovative medicines in three key therapeutic areas: oncology, neuroscience, and rare disease. Its dedication to oncology is exemplified by its expanding portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma, and pancreatic cancer.

Post-IPO Equity - Ipsen

Computer and Software Services and Scientific Services

Boulogne-billancourt

Ile-de-France

France

Europe

Ipsen posts strong third quarter results, raises outlook

Ipsen: Parvus AM Europe Ltd exceeds 5% of voting rights

Ipsen: second site wins Shingo award

Ipsen receives its second Shingo Prize for operational excellence

Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen

Ipsen reports EC approval of Kayfanda for cholestatic pruritus in ALGS

Ipsen’s Iqirvo approved in Europe

Ipsen: positive final data in advanced NETs

Employee of French drugmaker Ipsen to plead guilty to US insider trading

Ipsen sells priority review voucher for highest price since 2016

Ireland

United States

North America

Germany

Czech Republic

HTML5

Amazon Route 53

Modernizr

Google Drive

Google Fonts

jQuery

Bootstrap

Google Maps API

DigiCert

Adobe Flash

Ipsen owns Porton International, Inc.

Ipsen owns Ipsen Pharma SA

Ipsen owns Ipsen Pharma Biotech S.A.S.

Ipsen owns Biomeasure Inc.

Ipsen owns Beaufour- Ipsen Industrie S.A.S.

Ipsen is a French biopharmaceutical company focused on transformative medicines in oncology, rare disease, and neuroscience. It is one of the world's top 15 biopharmaceutical companies in terms of oncology sales. Founded in 1929 by Henri Beaufour, Ipsen has approximately 5,000 employees worldwide and its medicines are registered in more than 100 countries. The company is publicly traded on Euronext Paris and is family-owned, with the Beaufour family owning a majority of shares and voting rights.

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 4, 2024 10:53 AM	9c404167
crunchbase profile	general	Nov 4, 2024 11:05 AM	8ad8c26c
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	e11f0778
peers	general
news basic	general
bundesanzeiger	filings	Feb 12, 2024 5:26 PM	28791934
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

DE:IPSEN

Ipsen